CorMedix (CRMD) COO logs 5,794-share insider stock transaction

Rhea-AI Filing Summary

CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, reported a Form 4 insider transaction involving company common stock. On 01/12/2026, a transaction coded "F" was reported for 5,794 shares of common stock at a price of $7.15 per share. Following this transaction, she directly beneficially owned 160,301 shares of CorMedix common stock. The filing notes that the transaction is being reported late due to an inadvertent administrative error.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hurlburt Elizabeth

(Last) (First) (Middle)

C/O CORMEDIX INC.

300 CONNELL DRIVE, SUITE 4200

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026(1)		F		5,794	D	$7.15	160,301	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction is being reported late due to an inadvertent administrative error.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CorMedix (CRMD) report in this Form 4?

The Form 4 reports that Chief Operating Officer Elizabeth Hurlburt had a transaction coded "F" in CorMedix common stock on 01/12/2026 involving 5,794 shares at $7.15 per share.

How many CorMedix (CRMD) shares does the COO own after this transaction?

After the reported transaction, Chief Operating Officer Elizabeth Hurlburt beneficially owned 160,301 shares of CorMedix common stock directly.

Who is the reporting person in this CorMedix (CRMD) Form 4 filing?

The reporting person is Elizabeth Hurlburt, who serves as Chief Operating Officer of CorMedix Inc.

What does transaction code "F" indicate in this CorMedix Form 4?

The transaction is labeled with code "F" in the Form 4, which is the code used in the filing for this disposition of 5,794 common shares at $7.15 per share.

Was the CorMedix (CRMD) Form 4 filed on time?

The Form 4 states that the transaction is being reported late due to an inadvertent administrative error.

Is the COO’s ownership in CorMedix (CRMD) direct or indirect after the transaction?

The Form 4 indicates that the 160,301 shares beneficially owned following the transaction are held with direct ownership.